Eric Venker
CEO at Immunovant, Inc. (IMVT); CEO, President at Roivant Sciences Ltd. (ROIV)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $97.7M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 5SEC | IMVTImmunovant, Inc. | Sell | 3,506257,075 held (−1%) | $34.11 | $120K | -10.7% |
| Oct 2SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,599,154 held (−11%) | $36.62 | $7.3M | -3.2% |
| Sep 1SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 166,1821,632,972 held (−9%) | $35.63 | $5.9M | -0.5% |
| Sep 1SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 33,8181,599,154 held (−2%) | $36.44 | $1.2M | -2.7% |
| Jul 29SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,613,063 held (−11%) | $34.95 | $7.0M | +1.4% |
| Jul 6SEC | IMVTImmunovant, Inc. | Sell | 3,092254,280 held (−1%) | $38.48 | $119K | -20.8% |
| Jun 26SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 153,7661,659,297 held (−8%) | $33.05 | $5.1M | +7.2% |
| Jun 26SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 46,2341,613,063 held (−3%) | $33.51 | $1.5M | +5.8% |
| May 22SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,613,063 held (−11%) | $30.27 | $6.1M | +17.1% |
| Apr 22SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,647,546 held (−11%) | $29.59 | $5.9M | +19.8% |
| Apr 3SEC | IMVTImmunovant, Inc. | Sell | 12,82020,970 held (−38%) | $24.04 | $308K | +26.7% |
| Apr 3SEC | IMVTImmunovant, Inc. | Sell | 1,40919,561 held (−7%) | $24.60 | $35K | +23.9% |
| Mar 19SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,647,546 held (−11%) | $28.24 | $5.6M | +25.5% |
| Feb 18SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,654,597 held (−11%) | $26.49 | $5.3M | +33.8% |
| Jan 14SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,654,597 held (−11%) | $21.92 | $4.4M | +61.7% |
| Dec 29SEC | ROIVRoivant Sciences Ltd. | Sell | 200,0001,611,749 held (−11%) | $22.45 | $4.5M | +57.9% |
| Dec 29SEC | ROIVRoivant Sciences Ltd. | Sell | 75,0001,654,597 held (−4%) | $22.53 | $1.7M | +57.3% |
| Dec 11SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,497,908 held (−12%) | $20.85 | $4.2M | +70.0% |
| Nov 7SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 200,0001,504,959 held (−12%) | $20.22 | $4.0M | +75.3% |
| Oct 17SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 414,6831,504,959 held (−22%) | $16.93 | $7.0M | +109.3% |
| Oct 17SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 318,2821,504,959 held (−17%) | $17.05 | $5.4M | +107.9% |
| Oct 17SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 118,4181,504,959 held (−7%) | $17.06 | $2.0M | +107.7% |
| Oct 14SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 104,9401,504,959 held (−7%) | $16.30 | $1.7M | +117.4% |
| Oct 14SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 20,7271,504,959 held (−1%) | $16.25 | $337K | +118.1% |
| Oct 8SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 171,3961,504,959 held (−10%) | $16.34 | $2.8M | +116.9% |
| Oct 8SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 355,1611,504,959 held (−19%) | $16.15 | $5.7M | +119.4% |
| Oct 8SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 138,6021,504,959 held (−8%) | $16.20 | $2.2M | +118.8% |
- Sell
CEO, President Eric Venker sold $7.3M of ROIV at $36.62 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Eric Venker sold $5.9M of ROIV at $35.63 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Eric Venker sold $1.2M of ROIV at $36.44 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Eric Venker sold $7.0M of ROIV at $34.95 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Eric Venker sold $5.1M of ROIV at $33.05 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Eric Venker sold $1.5M of ROIV at $33.51 — pre-scheduled 10b5-1 plan sale.